Therapeutic agents such as bevacizumab (Avastin®), ranibizumab (Lucentis®), and aflibercept (Zaltrap®) (directed against vascular endothelial growth factor [VEGF]) are the first-line therapy for various retinal diseases, including neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) [34], but their use in BC treatment in combination with chemotherapy is increasing [35]. The gene discussed is VEGFA; the disease is wet macular degeneration.